Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
$33.99
$33.89
$17.00
$39.30
$1.63B2.59940,325 shsN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
$38.22
$38.12
$19.06
$40.14
$2.99B0.81.34 million shsN/A
Innoviva, Inc. stock logo
INVA
Innoviva
$19.20
-1.0%
$19.75
$16.21
$22.00
$1.21B0.37696,031 shs617,656 shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$114.39
+0.6%
$108.41
$81.74
$129.90
$2.21B0.84117,911 shs52,056 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$23.21
0.0%
$25.17
$11.16
$27.64
$1.07B0.48915,165 shs202,316 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Innoviva, Inc. stock logo
INVA
Innoviva
0.00%-3.81%-8.05%+8.35%+17.58%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
0.00%+0.21%+10.20%+14.88%+38.31%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.00%-1.17%-13.99%+0.45%+7.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
3.9129 of 5 stars
3.50.00.04.20.61.71.9
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4.8095 of 5 stars
3.53.00.04.42.73.31.9
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
3.4579 of 5 stars
2.22.00.03.92.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
0.00
N/AN/AN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
0.00
N/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
3.00
Buy$55.00186.46% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$146.1427.76% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.33
Hold$26.4413.96% Upside

Current Analyst Ratings Breakdown

Latest PCRX, DRNA, INVA, LGND, and CNST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.00
5/9/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $30.00
4/10/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$143.00
4/8/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/8/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$48.00 ➝ $65.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/AN/AN/AN/A$8.63 per shareN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
$164.31M18.17N/AN/A$1.84 per share20.77
Innoviva, Inc. stock logo
INVA
Innoviva
$358.71M3.36$3.42 per share5.61$11.03 per share1.74
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$167.13M13.20$1.60 per share71.31$43.95 per share2.60
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$700.97M1.53$4.31 per share5.38$16.86 per share1.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/A
Innoviva, Inc. stock logo
INVA
Innoviva
$23.39M-$1.01N/A12.39N/A-16.15%15.77%8.41%7/29/2025 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-$4.03M-$7.12N/A30.83N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-$99.56M-$2.28N/A9.03N/A-14.78%13.78%7.00%7/29/2025 (Estimated)

Latest PCRX, DRNA, INVA, LGND, and CNST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Innoviva, Inc. stock logo
INVA
Innoviva
$0.43N/AN/AN/A$87.10 millionN/A
7/29/2025Q2 2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.73N/AN/AN/A$183.11 millionN/A
5/8/2025Q1 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million
5/7/2025Q1 2025
Innoviva, Inc. stock logo
INVA
Innoviva
N/A$0.25N/A-$0.74N/A$88.63 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/AN/AN/AN/AN/A
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
N/A
15.39
15.39
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/A
2.46
2.46
Innoviva, Inc. stock logo
INVA
Innoviva
0.40
2.48
2.30
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/A
5.27
5.02
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.48
2.41
1.99
CompanyEmployeesShares OutstandingFree FloatOptionable
Constellation Pharmaceuticals, Inc. stock logo
CNST
Constellation Pharmaceuticals
15447.92 millionN/ANot Optionable
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
30278.13 million70.16 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
10062.78 million61.36 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.29 million17.94 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72046.29 million43.33 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Constellation Pharmaceuticals stock logo

Constellation Pharmaceuticals NASDAQ:CNST

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Dicerna Pharmaceuticals stock logo

Dicerna Pharmaceuticals NASDAQ:DRNA

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Innoviva stock logo

Innoviva NASDAQ:INVA

$19.20 -0.20 (-1.03%)
Closing price 07/3/2025 01:23 PM Eastern
Extended Trading
$19.20 0.00 (0.00%)
As of 07/3/2025 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$114.38 +0.73 (+0.64%)
As of 07/3/2025 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$23.20 -0.01 (-0.02%)
As of 07/3/2025 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.